JP2020516647A5 - - Google Patents

Info

Publication number

JP2020516647A5

JP2020516647A5 JP2019555854A JP2019555854A JP2020516647A5 JP 2020516647 A5 JP2020516647 A5 JP 2020516647A5 JP 2019555854 A JP2019555854 A JP 2019555854A JP 2019555854 A JP2019555854 A JP 2019555854A JP 2020516647 A5 JP2020516647 A5 JP 2020516647A5

Authority

JP

Japan

Prior art keywords

antibody

seq

amino acid

acid sequence

tslp

Prior art date

2018-04-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003275 alpha amino acid group Chemical group 0.000 claims description 168
• 230000027455 binding Effects 0.000 claims description 106
• 238000009739 binding Methods 0.000 claims description 106
• 238000000034 method Methods 0.000 claims description 92
• 102000040430 polynucleotide Human genes 0.000 claims description 66
• 108091033319 polynucleotide Proteins 0.000 claims description 66
• 239000002157 polynucleotide Substances 0.000 claims description 66
• 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims description 59
• 239000000427 antigen Substances 0.000 claims description 47
• 102000036639 antigens Human genes 0.000 claims description 47
• 108091007433 antigens Proteins 0.000 claims description 47
• 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims description 40
• 208000006673 asthma Diseases 0.000 claims description 38
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 34
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 34
• 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims description 34
• 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 34
• 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims description 34
• 230000000295 complement effect Effects 0.000 claims description 22
• 210000003979 eosinophil Anatomy 0.000 claims description 20
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 19
• 150000001413 amino acids Chemical class 0.000 claims description 19
• 210000004027 cell Anatomy 0.000 claims description 10
• 230000000694 effects Effects 0.000 claims description 7
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 6
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 6
• 102000025171 antigen binding proteins Human genes 0.000 claims description 5
• 108091000831 antigen binding proteins Proteins 0.000 claims description 5
• 238000002560 therapeutic procedure Methods 0.000 claims description 5
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
• 238000011260 co-administration Methods 0.000 claims description 4
• 239000003246 corticosteroid Substances 0.000 claims description 4
• 238000003745 diagnosis Methods 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 230000002401 inhibitory effect Effects 0.000 claims description 4
• 238000001990 intravenous administration Methods 0.000 claims description 4
• 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 4
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
• 238000007920 subcutaneous administration Methods 0.000 claims description 4
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 4
• 239000000178 monomer Substances 0.000 claims description 3
• PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 claims description 2
• 238000013313 FeNO test Methods 0.000 claims description 2
• 206010036790 Productive cough Diseases 0.000 claims description 2
• 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
• 210000004369 blood Anatomy 0.000 claims description 2
• 239000008280 blood Substances 0.000 claims description 2
• 239000012530 fluid Substances 0.000 claims description 2
• 229940127212 long-acting beta 2 agonist Drugs 0.000 claims description 2
• 229940125389 long-acting beta agonist Drugs 0.000 claims description 2
• 210000004072 lung Anatomy 0.000 claims description 2
• 239000003149 muscarinic antagonist Substances 0.000 claims description 2
• 229940124624 oral corticosteroid Drugs 0.000 claims description 2
• 210000003802 sputum Anatomy 0.000 claims description 2
• 208000024794 sputum Diseases 0.000 claims description 2
• 208000024891 symptom Diseases 0.000 claims description 2
• 229960000278 theophylline Drugs 0.000 claims description 2
• 239000012634 fragment Substances 0.000 claims 43
• 239000000203 mixture Substances 0.000 claims 39
• 208000037874 Asthma exacerbation Diseases 0.000 claims 2
• 229940124748 beta 2 agonist Drugs 0.000 claims 1
• OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 claims 1
• 230000003111 delayed effect Effects 0.000 claims 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
• 239000000556 agonist Substances 0.000 description 1
• 230000001934 delay Effects 0.000 description 1